- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Vaccination
Intervention: Pharmacological intervention
This refers to the drug, therapy, or factor being studied in a clinical trial or observational study. Examples include antiviral agents monoclonal antibodies, corticosteroids, vaccines and other pharmacological agents
- Adults (18-64 years)
- Elderly (≥65 years)
- Pregnant women
- Hospital
- Outpatient clinic
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Vaccination
- Nirsevimab
- Abrysvo
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- Elderly (≥65 years)
- People at high risk of STIs
- Men who have sex with men
- PrEP users
- Outpatient clinic
- Monkeypox virus
- Mpox
- Sexually transmitted infection
- Serum
- Pharmacological intervention
- Vaccination
- MVA-BN
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- Monkeypox virus
- Mpox
- Sexually transmitted infection
- Blood sample
- PBMC
- Pharmacological intervention
- Vaccination
- JYNNEOS
- Dryvax
- Adults (18-64 years)
- People at high risk of STIs
- STD/STI clinic
- Monkeypox virus
- Mpox
- Sexually transmitted infection
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- Outpatient clinic
- Community
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Immunomodulator
- Colchicine
- Metformin
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Children (1-11 years)
- Outpatient clinic
- Arbovirus
- Dengue virus
- Vector-borne disease
- Arboviral disease
- Vector-borne disease
- Blood sample
- Pharmacological intervention
- Vaccination
- Qdenga
- Adults (18-64 years)
- Elderly (≥65 years)
- People at high risk of STIs
- Men who have sex with men
- PrEP users
- Non-hospital health centre
- STD/STI clinic
- Chlamydia trachomatis
- Neisseria gonorrhoeae
- Treponema pallidum
- HIV
- Mycoplasma genitalium
- Hepatitis
- Sexually transmitted infection
- Anal-rectal swab
- Oral swab
- Urethral exudate
- Pharmacological intervention
- PrEP-HIV
- Adults (18-64 years)
- Elderly (≥65 years)
- People at high risk of STIs
- Men who have sex with men
- PrEP users
- Primary care
- Non-hospital health centre
- STD/STI clinic
- Chlamydia trachomatis
- Neisseria gonorrhoeae
- Treponema pallidum
- Sexually transmitted infection
- Syphilis
- Pharmacological intervention
- Antivirals
- PrEP-HIV